BCYC
Price
$8.07
Change
+$0.02 (+0.25%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
560.96M
68 days until earnings call
LYRA
Price
$0.09
Change
-$0.00 (-0.00%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
6.12M
80 days until earnings call
Interact to see
Advertisement

BCYC vs LYRA

Header iconBCYC vs LYRA Comparison
Open Charts BCYC vs LYRABanner chart's image
Bicycle Therapeutics
Price$8.07
Change+$0.02 (+0.25%)
Volume$564
Capitalization560.96M
Lyra Therapeutics
Price$0.09
Change-$0.00 (-0.00%)
Volume$2.54K
Capitalization6.12M
BCYC vs LYRA Comparison Chart
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. LYRA commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and LYRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (BCYC: $8.05 vs. LYRA: $0.09)
Brand notoriety: BCYC and LYRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 0% vs. LYRA: 34%
Market capitalization -- BCYC: $560.96M vs. LYRA: $6.12M
BCYC [@Biotechnology] is valued at $560.96M. LYRA’s [@Biotechnology] market capitalization is $6.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileLYRA’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • LYRA’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCYC and LYRA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 3 TA indicator(s) are bullish while LYRA’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 3 bullish, 4 bearish.
  • LYRA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, LYRA is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -0.86% price change this week, while LYRA (@Biotechnology) price change was -18.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

LYRA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($561M) has a higher market cap than LYRA($6.12M). BCYC YTD gains are higher at: -42.500 vs. LYRA (-55.233). LYRA has higher annual earnings (EBITDA): -44.7M vs. BCYC (-200.61M). BCYC has more cash in the bank: 793M vs. LYRA (31.7M). BCYC has less debt than LYRA: BCYC (8.33M) vs LYRA (33.4M). BCYC has higher revenues than LYRA: BCYC (25.7M) vs LYRA (1.19M).
BCYCLYRABCYC / LYRA
Capitalization561M6.12M9,162%
EBITDA-200.61M-44.7M449%
Gain YTD-42.500-55.23377%
P/E RatioN/AN/A-
Revenue25.7M1.19M2,169%
Total Cash793M31.7M2,502%
Total Debt8.33M33.4M25%
FUNDAMENTALS RATINGS
BCYC: Fundamental Ratings
BCYC
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCYCLYRA
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DT54.190.59
+1.10%
Dynatrace
MX3.90N/A
N/A
Magnachip Semiconductor Corp
JJSF112.60-0.98
-0.86%
J & J Snack Foods Corp
IFBD1.05-0.02
-1.78%
Infobird Co Ltd
KIDS21.15-0.70
-3.20%
OrthoPediatrics Corp

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
N/A
INO - BCYC
55%
Loosely correlated
+2.02%
XNCR - BCYC
54%
Loosely correlated
+2.26%
RPTX - BCYC
51%
Loosely correlated
N/A
RLAY - BCYC
49%
Loosely correlated
N/A
RCKT - BCYC
46%
Loosely correlated
N/A
More

LYRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been closely correlated with GLYC. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then GLYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-1.70%
GLYC - LYRA
75%
Closely correlated
N/A
EYPT - LYRA
58%
Loosely correlated
-4.60%
ATOS - LYRA
37%
Loosely correlated
-0.09%
ERAS - LYRA
29%
Poorly correlated
N/A
SQZB - LYRA
29%
Poorly correlated
N/A
More